NDRM NeuroDerm Ltd.

28.80
+0  (1%)
Previous Close 28.50
Open 28.60
Price To book 5.02
Market Cap 758.53M
Shares 26,338,000
Volume 92,048
Short Ratio 2.03
Av. Daily Volume 232,600

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial met key primary and secondary endpoints - March 1, 2017.
ND0612H (Trial 006)
Severe Parkinson's Disease
Phase 3 trial suspended, to be replaced by comparative PK trial due to be initiated 2H 2017.
ND0612L
Parkinson's Disease